Background: Hsp90-beta has been investigated to be correlated with the occurrence and development of tumor.\nThe intention of this research was to test the level of Hsp90-beta in malignant pleural effusion (MPE) of patients\nwith lung cancer and disclose the clinical significance of Hsp90-beta as a potential tumor marker for differential\ndiagnosis of pleural effusion caused by lung cancer.\nMethods: The level of Hsp90-beta was determined using enzyme-linked immunosorbent assay. Calculations of\nthe Hsp90-beta threshold, the sensitivity and specificity for distinguishing MPE from benign pleural effusion were\nperformed using receiver operator characteristic curve.\nResults: The level of Hsp90-beta in MPE of lung cancer patients was higher than that in control individuals\n(P < 0.05) and increased MPE Hsp90-beta was correlated with the pathological differentiation, tumor size and\nlymphatic metastasis (P < 0.05). The cutoff value of Hsp90-beta produced by receiver operator characteristic\ncurve for distinguishing lung cancer from control individuals were 1.659 ng/mL and the sensitivity and specificity\nwere 93.46 and 79%.\nConclusions: Increased Hsp90-beta in MPE was correlated with malignant biological behavior of lung cancer\npatients, indicating that the level of Hsp90-beta could be a tool of referential value for differential diagnosis of\npleural effusion caused by lung cancer.
Loading....